Rare diseases
Investigational molecules
Locations
Via Palermo 26/a, 43122 Parma, Italy
Chiesi Farmaceutici S.p.A. is active in clinical research for asthma, including uncontrolled asthma, mild to moderate asthma, and moderate to severe controlled asthma. Its studies also address asthma exacerbations, lung function, and symptom control in patients receiving inhaled maintenance therapy.
The sponsor’s respiratory portfolio includes work on inhaled treatments for persistent airway disease and the optimization of combination inhaler approaches in patients with chronic respiratory symptoms.
Chiesi Farmaceutici S.p.A. runs clinical trials in conditions such as Asthma, Chronic obstructive pulmonary disease, Fabry's disease, Partial lipodystrophy, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease
AustriaStudy on the Effects of Metreleptin for Patients with Partial Lipodystrophy
FranceAsthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate
BulgariaSafety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures
AustriaA study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis
BelgiumStudy comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy
GermanyStudy on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
AustriaStudy on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
AustriaStudy on the Effectiveness and Safety of CHF 5993 Compared to CHF 1535 for Patients with Chronic Obstructive Pulmonary Disease (COPD)
BulgariaStudy on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma
BulgariaComparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma
BulgariaEvaluation of lung delivery and systemic exposure of inhaled beclometasone dipropionate and beclometasone dipropionate anhydrous for asthma in healthy adult volunteers
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
